80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
Title:
80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
Author:
Felip, E. Altorki, N.K. Zhou, C. Vallieres, E. Vynnychenko, I.O. Akopov, A. Martinez-Marti, A. Chella, A. Bondarenko, I. Ursol, G. Levchenko, E. Kislov, N. Liersch, R. Belleli, R. McNally, V.A. Bennett, E. Gitlitz, B.J. Wakelee, H.